I underwrite a much larger
installed base, better recurring mix from software, parts, support and operations, and real but gradual diversification into healthcare, wholesale grocery and adjacent formats. I do not assume a euphoric
rerating: the stock can work with some multiple normalization because revenue quality should improve, but concentration, physical deployment intensity and governance overhangs likely prevent a best-in-class software premium.